EULAR系统性红斑狼疮推荐临床实施的实用专家建议
该文由八位国际SLE专家通过包含17个开放式问题的在线调查,就早期诊断、治疗目标及糖皮质激素、免疫抑制剂和生物制剂的使用达成共识。专家建议围绕设定标准化目标、采取行动达标、监测达标和优化治疗策略四个主题,形成13条核心建议,以促进EULAR推荐在常规临床实践中的实施。
要点
- 专家建议设定标准化治疗目标以改变疾病病程并预防器官损害。
- 需采取行动实现治疗目标,并通过验证的临床工具和框架监测达标情况。
- 优化治疗策略以预防复发和糖皮质激素相关毒性,包括考虑早期使用生物制剂和激素减量。
核心结论
- 专家见解可促进EULAR系统性红斑狼疮管理推荐在临床实践中的实施,帮助患者达到治疗目标并预防和/或延缓器官损害进展。
研究设计与样本
- 八位国际SLE专家通过包含17个开放式问题的在线调查提供意见,调查内容涉及EULAR推荐中早期诊断、治疗目标及糖皮质激素、免疫抑制剂和生物制剂的使用。
- 调查结果经汇编和分析,就每个主题的关键建议点达成共识。
主要发现
- 专家建议覆盖四个关键主题:设定标准化目标以帮助改变疾病病程和预防器官损害;采取行动实现这些目标;通过验证的临床工具和框架监测目标达成;优化治疗策略以预防复发和糖皮质激素相关毒性。
- 在这些主题下共形成13条核心专家建议,包括考虑更早使用生物制剂和/或传统免疫抑制剂的情景、影响治疗决策的预后较差特定风险因素以及糖皮质激素减量建议。
关键数值与推荐
- 共形成13条核心专家建议,覆盖设定标准化目标、采取行动达标、监测达标和优化治疗策略四个主题。
临床怎么用
- 临床医生可参考这些专家建议,在常规实践中更有效和高效地实施EULAR系统性红斑狼疮管理推荐。
- 建议包括在特定情景下考虑更早使用生物制剂和/或传统免疫抑制剂,以及根据预后较差风险因素调整治疗决策和进行糖皮质激素减量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of systemic lupus erythematosus (SLE) and lupus nephritis provide important guidance for practitioners on diagnosis, monitoring and treatment. However, practical barriers, such as time constraints, may pose challenges to practitioners when implementing these recommendations in real-world settings. We provide practical, expert-driven advice on how practitioners may effectively and efficiently implement the EULAR recommendations in routine clinical practice. METHODS: Eight international SLE experts convened and contributed opinions and advice for practitioners via an online survey containing 17 open-ended questions on implementation of the EULAR recommendations for early diagnosis, treatment targets and the use of glucocorticoids (GCs), immunosuppressants and biologics. Survey results were compiled and analysed to reach consensus on key advice points for each topic. RESULTS: Expert advice covered four key topics-setting standardised targets to help modify disease course and prevent organ damage; taking action to achieve these targets; monitoring of target achievement through validated clinical tools and frameworks; and optimising the therapeutic strategy to prevent flares and GC-associated toxicities. A total of 13 core expert-driven advice points were developed across these topics, including scenarios for consideration of earlier biological and/or conventional immunosuppressive use, specific risk factors for poorer prognosis to inform treatment decisions and suggestions on GC tapering. CONCLUSIONS: These expert insights could facilitate implementation of the EULAR recommendations for the management of SLE in clinical practice, thereby helping patients achieve treatment targets and prevent and/or delay organ damage progression.
引用
- Parodis I, Fanouriakis A, Bortoluzzi A, et al. Practical insights for the clinical implementation of the EULAR recommendations for patients with systemic lupus erythematosus. RMD Open. 2025. PMID: 41475837. doi:10.1136/rmdopen-2025-006210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。